GSK, Adolor stop trials of Entereg over heart risk

04/9/2007 | Age (Melbourne, Australia), The

GlaxoSmithKline and its partner, Adolor Corp., said the drug was designed to treat constipation problems tied to opioid painkillers. But negative findings from a Phase III study found 2.6% of patients treated with Entereg suffered heart problems compared with 1.1% of patients treated with placebos.

View Full Article in:

Age (Melbourne, Australia), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY